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Abstract Glutamate, a nonessential amino acid, is a
major bioenergetic substrate for proliferating normal and
neoplastic cells on one hand and an excitatory neuro-
transmitter that is actively involved in biosynthetic, bio-
energetic, metabolic, and oncogenic signaling pathways on
the other. It exerts its action through a family of receptors
consisting of metabotropic glutamate receptors (mGluRs)
and ionotropic glutamate receptors (iGluRs), both of which
have been implicated previously in a broad spectrum of
acute and chronic neurodegenerative diseases. In this
review, we discuss existing data on the role of glutamate as
a growth factor for neoplastic cells, the expression of
glutamate receptors in various types of benign and malig-
nant neoplasms, and the potential roles that GluRs play in
cancer development and progression along with their
clinical significance. We conclude that glutamate-related
receptors and their signaling pathways may provide novel
therapeutic opportunities for a variety of malignant human
diseases.
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Introduction
Glutamate (Glu) is one of the key neurotransmitters in the
mammalian central nervous system responsible for fast
excitatory synaptic signaling in the brain. It affects several
physiological processes such us learning, memory or
behavior. High levels of Glu resulting in activation of
respective receptors lead to neuronal cell death called ex-
citotoxicity that is involved in pathophysiology of various
neurodegenerative diseases, epilepsy, hypoxia or stroke
(Peng et al. 2011).
To exert its function, glutamate requires apt receptors.
Their structure and function were recently reviewed in
detail (Lau and Tymianski 2010), thereby we only want to
stress that glutamate receptors constitute two main groups:
metabotropic glutamate receptors (mGluRs), which belong
to the superfamily of G-protein coupled receptors, and
ionotropic receptors (iGluRs), which form ion channels.
Based on the sequence homology and intracellular signal
transduction mechanisms, mGluRs have been classified
into three subgroups: mGluR1 and mGluR5, coupled to the
phospholipase C, belong to group I; group II consists of
mGluR2 and mGluR3, whereas group III contains
mGluR4, mGluR6, mGluR7 and mGluR8, which are all
negatively coupled to adenylate cyclase. Metabotropic
GluRs function as dimers, with two glutamate molecules
being required for full receptor activation.
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Likewise, the iGluRs are divided into three groups based
on structural similarities and named according to the type
of synthetic agonist that activates them: N-methyl-D-
aspartate (NMDA) receptors (NMDARs), amino-3-
hydroxy-5-methyl-4-isoxazolepropionate (AMPA) recep-
tors (AMPARs), and 2-carboxy-3-carboxymethyl-4-iso-
propenylpyrrolidine (kainate, KA) receptors (KARs).
NMDARs are assembled from seven subunits: NR1,
NR2A/B/C/D, NR3A/B, each one being a product of a
separate gene. Alternative splicing results in additional
heterogeneity of NMDAR subunits. NMDARs consist of
two obligatory NR1 subunits and two of four types of
regulatory subunits, NR2A, B, C and D, which assemble as
a dimer of dimers. The resulting complex might eventually
join with either NR3A or NR3B, which, in such a case,
replaces one of the NR2 subunits. Moreover, glycine is a
requisite natural agonist for NMDARs (Kew and Kemp
2005; Mayer 2005). For the NMDARs, the NR1 subunit is
necessary for calcium conductivity of the channel, while
NR2 and NR3 subunits determine electrophysiological and
pharmacological properties of the receptor (Traynelis et al.
2010).
AMPA receptors are composed of four subunits: GluR1/
2/3/4, that show 70 % of homology while being products of
separate genes. Similarly to NMDARs, functional AM-
PARs are heterotetramers. Within the receptor, the GluR2
subunit plays a critical role in the determination of the
Ca2? permeability of the AMPARs. Interestingly, the
genomic DNA of the GluR2 subunit contains a code for a
glutamine (Q) residue at amino acid 607, but during the
process of nuclear RNA-editing glutamine is replaced by
arginine (R) in the vast majority of neuronal cells, which
results in a very low calcium permeability for receptors
containing the GluR2 subunit (Kew and Kemp 2005; Lau
and Tymianski 2010; Palmer et al. 2005).
Kainate receptors comprise two types of subunits:
GluR5/6/7 and KA1 and KA2, which form homo or het-
erotetramers. Fully functional homotetrameric receptors
are composed of GluR5–7 subunits. KA1/2 homotetramers,
even though they combine with the agonist, remain inac-
tive. Functional receptors that consist of KA1/2 subunits
have heterotetrameric form in conjunction with GluR5/6/7
subunits. Interestingly, GluR2, GluR5 and GluR6 undergo
glutamine/arginine editing (Contractor et al. 2011).
Therefore, an opportunity of receptors formation with
distinct physicochemical and pharmacological properties
exists due to the diversity of ionotropic receptor subunits.
Glutamate as a growth factor for cancer cells
Glutamate has been proven to regulate proliferation,
migration, and survival of neuronal progenitor cells and
immature neurons during brain development (Ikonomidou
et al. 1999; Komuro and Rakic 1993). The ability of
uncontrollable propagation and migration characterizes
neoplastic cells as well; therefore, glutamate was suggested
as a potential growth factor in tumor development. Support
for this hypothesis was provided by studies that showed the
generation of neurotoxic quantities of glutamate by glial
tumor cells ex vivo (in surgical specimens) (Takano et al.
2001) as well as in vitro in glioma cell lines, where
extracellular glutamate concentrations up to 500 lmol/L
were demonstrated (Ye and Sontheimer 1999). Follow-up
studies confirmed that glutamate stimulates glioma cells
proliferation in vivo. Moreover, genetic modifications of
C6 rat glioma cells facilitated creation of cell lines that
release excessive amounts of Glu along with non-secreting
lines. Subsequent xenograft studies proved that experi-
mental tumors created from cells that release high amounts
of Glu grow more aggressively than those from non-
modified cells (which release moderate amounts of Glu) or
from non-secreting cells; this phenomenon was closely
related to animals’ overall survival times (Takano et al.
2001). Recent studies showed also that excessive glutamate
concentrations (in the range of 100 lM) might be found in
the extracellular space at the tumor margin in glioblastoma-
bearing patients (de Groot and Sontheimer 2011) resulting
in neuronal cell death, which in turn facilitates tumor
growth (Rothstein and Brem 2001) and possibly relates to
epileptic seizures in glioma patients (Oberndorfer et al.
2002). Interestingly, the latter observation has recently
been supported by a study that proved the relationship
between increased levels of an excitatory neuropeptide,
dynorphin 1–17 that comprises glutamate, and cell death or
surgery-related tissue injury in vivo in epilepsy patients
(Broderick et al. 2008). Such levels of Glu might arise from
glutamate uptake/release systems that are aberrantly
expressed and/or activated in glioma cells. It has also been
proven that glutamate release in gliomas is, at least in part,
mediated by a Na?-independent cystine–glutamate
exchanger XC
- system, expressed in glioma cell lines and
patient-derived glioma cells (Lyons et al. 2007). Pharma-
cologic inhibition of this system slows tumor growth and
extends survival of tumor-bearing animals (Chung et al.
2005). Importantly, XC
- system seems to be up-regulated in
glioma cells acting in concert with the lack of functional
Na?-dependent transport systems of the excitatory amino
acid transporters (EAATs), which are responsible for glu-
tamate uptake and are amply expressed in nonmalignant
glial cells (Lyons et al. 2007; Sontheimer 2008). In glioma
cells, EAAT1/2 transporters (especially EAAT2) seem to
inversely correlate with the degree of malignancy with
almost no expression in GBMs (de Groot and Sontheimer
2011). Accordingly, glioma cells not only release Glu to
enhance their highly malignant behavior but also are
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incapable of its reuptake. More recently, it has also been
demonstrated that cells from non-CNS cancers may secrete
Glu. MDA-MB-231 (human breast), B16F1 (mouse mela-
noma) and MATLyLu (rat prostate) cancer cell lines
release significant quantities of glutamate into their extra-
cellular environment (Seidlitz et al. 2009). A very recent
study reported that prostate cancer-bearing patients have
serum glutamate levels directly correlating with Gleason
score (B6 vs. C8) and primary prostate cancer aggres-
siveness (Koochekpour 2013). Glutamate tissue levels in
fresh frozen human normal pancreatic tissue, chronic
pancreatitis (CP) and pancreatic ductal adenocarcinoma
(PDAC) tissues demonstrated a striking increase of gluta-
mate in CP and PDAC samples, suggesting that Glu might
serve as a molecular switch that decreases the threshold of
k-ras-induced oncogenic signaling and increases the
chance of malignant transformation of pancreatic cancer
precursor lesions (Herner et al. 2011). Glutamate and
synthetic GluR agonists stimulated proliferation of A549
lung cancer cells in vitro (Rzeski et al. 2001; Stepulak et al.
2005, 2007) and invasion of PDAC (Herner et al. 2011).
Thereby, released Glu can act as a growth factor and a
signal mediator in non-neuronal tumor tissues, in both,
autocrine and paracrine fashions.
Expression of glutamate receptors in cancer cells
A long-standing paradigm suggested that glutamate sig-
naling is limited to the central nervous system. Recently,
however this opinion has been changed owing to the
studies that proved glutamate receptors’ existence in
peripheral organs and neoplastic cells (Hinoi et al. 2004;
Kalariti et al. 2005). First studies in the mid-nineties of the
last century provided evidence that labeled NMDA agonist
([3H]MK801) couples with CNS tumor cells; moreover,
in vitro glutamate application resulted in Ca2? influx into
those cells (Ohkuma et al. 1994). Follow-up studies proved
the existence of ionotropic GluR1 and GluR4 (Korczak
et al. 1995), GluR2/3/4/6/7, KA1 (Yoshioka et al. 1996)],
NR1 and NR2C (Casado et al. 1996), or GluR1/2/3/4 in
surgical samples of glioblastomas (Ishiuchi et al. 2002)
along with various other combinations of subunits in cell
lines and CNS tumor samples (Aronica et al. 2001; de
Groot et al. 2008). It has been also demonstrated that
glutamate receptor subunits are expressed in a variety of
cancer cell lines and tumors, originating outside of CNS
such as colorectal (Chang et al. 2005; Yoo et al. 2004),
pancreatic (Herner et al. 2011), hepatocellular (Li et al.
2012) or gastric cancer (Liu et al. 2007), breast cancer
(North et al. 2010b), ovarian cancer (Choi et al. 2012), lung
cancers (North et al. 2010a), thyroid cancer (Stepulak et al.
2009), oral squamous cell carcinoma (SCC) (Park et al.
2007), larynx cancer (Stepulak et al. 2011), prostate cancer
(Abdul and Hoosein 2005), melanoma (Marin and Chen
2004; Pollock et al. 2003) or osteosarcoma (Kalariti et al.
2004), as well as blood neoplasms such as leukemia and
lymphoma (Ganor et al. 2009). Still, the majority of the
existing studies describe single receptor or its subunit
expression in selected types of cancers while a more
detailed analysis of glutamate receptor subunit expression
in cancer cell lines or solid tumors remains scarce. Hence,
we decided to analyze the presence of iGluRs and mGluRs
receptor subunits in several cancer cell lines of neuronal
and non-neuronal origin. These studies revealed differen-
tial patterns of receptor subunit expression, with some
specificity for particular neoplasms (Stepulak et al. 2009,
2011). Interestingly, the NR1 subunit of the NMDA
receptor, although present in other cell lines derived from
CNS neoplasms, was lacking in glioma cell lines (Stepulak
et al. 2009), thereby suggesting that NMDARs are not
functional in glioma cells. This observation is supported by
previous studies, which showed that four analyzed glioma
cell lines and patient-derived gliomas were devoid of NR1
subunit (Lyons et al. 2007) or that its expression was very
rare in pediatric GBMs (Brocke et al. 2010).
In contrast to NMDARs, AMPA receptors are abun-
dantly expressed in glioma cells, where they play an
important role in glutamate-mediated proliferative signals
thus enhancing its malignant phenotype (de Groot and
Sontheimer 2011; Sontheimer 2008). As a matter of fact,
all AMPA receptor subunits were found in CNS-derived
tumors (Aronica et al. 2001; de Groot and Sontheimer
2011; Ishiuchi et al. 2002). Furthermore, the presence or
lack of GluR2 subunit seems to be crucial for glioma cells
invasion potential. It was observed that the majority of
invasive gliomas either lack GluR2 expression (Lyons et al.
2007) or GluR2 is expressed at significantly lower levels,
as demonstrated in highly malignant pediatric glioblasto-
mas, ependymomas or medulloblastomas (all WHO III or
IV) in contrast to low-grade astrocytomas (WHO I or II)
(Brocke et al. 2010). Additionally, RNAi experiments in a
low-grade glioma cell line demonstrated that down-regu-
lation of GluR2 expression caused a significant increase of
cell proliferation (Beretta et al. 2009). On the other hand,
over-expression of edited GluR2 subunit by adenovirus-
mediated transfer inhibited migration of glioma cells both
in vitro and in vivo (Ishiuchi et al. 2002), proving that
Ca2?-permeable AMPA receptors are crucial for glioma
invasion.
Importantly, the presence of unedited (Q) or edited
(R) GluR2 (Q/R site) subunit is critical for calcium per-
meability of AMPA receptor. Developmentally controlled
replacement of the arginine with glutamine at this critical
site (Q/R site) during an RNA-editing process renders
AMPA receptors permeable (unedited GluR2) or non-
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permeable to Ca2? (Hollmann and Heinemann 1994; See-
burg 1993). Edited form of GluR2 exists exclusively in the
adult brain while unedited forms are present in the fetal
brain (Burnashev et al. 1992) and in some cancer cells or
tumors (Brocke et al. 2010; Maas et al. 2001; Stepulak
et al. 2009; Yoshida et al. 2006). When analyzing GluR2
Q/R-editing status in different cancer cell lines, it has been
shown that some of them exclusively express the unedited
form of GluR2 (SK-NA-S, neuroblastoma) or both, the
edited and the unedited GluR2 forms (MOGGCCM,
astrocytoma). Interestingly, unedited GluR2 RNA was
found also in SK-LU-1 lung cancer cells (Stepulak et al.
2009), forming highly malignant tumors with a tendency to
set distant metastases. This shows that cancer cells could
express AMPA receptor forms characteristic for Ca2?-
permeable fetal cells, which could in turn contribute to
cancer cells’ invasion potential, as it has been demon-
strated for glioma cells (Ishiuchi et al. 2002). Of particular
interest is the fact that glioblastoma-tumor initiating cells
express high levels of functional, calcium-permeable
AMPA receptors containing GluR1 and GluR4 subunits,
when compared with the differentiated tumor cultures
consisting of non-stem cells derived from the same tumor
tissues (Oh et al. 2012). These finding suggests that func-
tional AMPA receptors can be formed in specific areas of
the tumor.
As mentioned above, in contrast to AMPARs, NMDARs
expression is reported mainly in peripheral cancers. Mod-
erate to high expression of NR1 subunit of NMDAR has
been demonstrated in prostate cancer samples, whereas its
expression in normal prostate tissue and benign prostate
hyperplasia was very low or absent. Similar expression
pattern was found in normal colon or cancer specimens
(Abdul and Hoosein 2005). NR1 subunit immunohisto-
chemical reactivity was observed in the majority of small-
cell lung (North et al. 2010a) or breast cancer samples,
where NR2B subunit was also detected (North et al.
2010b). Different combinations or single subunits of
NMDARs were demonstrated in cell lines derived from
colon cancer (Stepulak et al. 2009; Yamaguchi et al. 2013),
breast cancer (North et al. 2010b; Stepulak et al. 2009),
oral cancer (Choi et al. 2004), laryngeal carcinoma (Step-
ulak et al. 2011), lung cancers (North et al. 2010a; Stepulak
et al. 2005, 2007), prostate cancer (Abdul and Hoosein
2005), thyroid cancer (Stepulak et al. 2009) as well as in
gastric (Liu et al. 2007; Watanabe et al. 2008), esophageal
(Kim et al. 2006), and hepatocellular carcinomas (Yam-
aguchi et al. 2013).
Interestingly, the expression of kainate receptors in
cancer cells has not been extensively studied. The presence
of GluR5–7 subunits in human glioneuronal tumors
(Aronica et al. 2001), GluR5–7 and KA1 in medulloblas-
tomas, and additionally KA2 subunit in neuroblastoma cell
lines (Yoshioka et al. 1996) or retinoblastoma cells (Tak-
eda et al. 2000) has been reported. Genome-wide associa-
tion studies have recently identified GluR5 expression in
hepatocellular carcinoma samples (Li et al. 2012), whereas
GluR6 subunits were detected in gastric cancer tissue and
gastric cancer cell lines (Wu et al. 2010).
Likewise, our earlier study demonstrated the presence of
GluR5 in U343 glioma cells, whereas GluR6, GluR7, KA1
and KA2 subunits were found in all 12 analyzed cancer cell
lines, which suggests a role of kainate receptors in
metabolism and proliferation of cancer cells (Stepulak
et al. 2009). However, when analyzing relative glutamate
receptor subunit amounts in cancer cells in comparison to
their expression in normal human brain on mRNA level,
significant differences were observed. As measured by
means of real-time PCR technique, the majority of cancer
cell lines expressed either NMDA or AMPA/kainate
receptor subunits at much lower levels than the normal
human brain (HB). NMDAR NR2B subunit expression
level in cancer cell lines was very low compared to HB,
with the exception of the human colon adenocarcinoma cell
line LS180, which showed an expression level approxi-
mating 50 % of the estimated level of NR2B subunit
expression in HB. Similarly, a strong expression of GluR4
AMPA receptor subunit was detected in two cell lines:
TE671 (rhabdomyosarcoma/medulloblastoma) and RPMI
(plasmocytoma), and of GluR6 kainate receptor subunit in
SK-NA-S (neuroblastoma) and MOGGCCM (astrocytoma)
cell lines at levels comparable to those in the HB. Similar
levels of expression of KA2 were found also in human
TE671 and the HB (Stepulak et al. 2009).
Glutamate receptor subunits have different expression
patterns in pediatric CNS tumors as well. Expression of
NR2D, NR3A, KA1, GluR4, mGluR1, mGluR4, mGluR5
and mGluR6 was higher in the high-grade tumors com-
pared to human brain. In low-grade astrocytomas, expres-
sion of these glutamate receptor subunits was comparable
or lower than in HB (Brocke et al. 2010).
Aforementioned studies provide compelling evidence
that glutamate receptors are expressed at higher level in the
tumors and neoplastic cell lines of brain origin than in
those derived from peripheral cancers. The observation that
GluRs subunits, which are poorly represented in the adult
brain, are expressed in cancer cells (Stepulak et al. 2009) is
of interest as well. On the other hand, it has been shown
that the expression of NMDA receptor subunits in the brain
varies during development; especially NR2D subunits are
present at high levels prenatally in rapidly dividing CNS
cells with subsequent decrease postnatally. In adults,
NR2D presence is limited to small numbers of cells in
selected regions of the brain (Cull-Candy et al. 2001;
Waxman and Lynch 2005). Thus, expression of NR2D
subunits in all the virtually analyzed cancer cell lines
936 A. Stepulak et al.
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(Stepulak et al. 2009) suggests that the re-expression of
NR2D in cancer cells may correlate with their proliferative
potential. Interestingly, silencing of NR2D subunit did not
influence cancer cells phenotypes. The same was observed
for KA2 subunit, also present in all cancer cell lines ana-
lyzed (Luksch et al. 2011).
The next important question is whether glutamate
receptors are functional in cancer cells. Some observations
suggest such a possibility. It has been demonstrated with
patch-clamp electrophysiological recordings that glutamate
might evoke whole-cell currents in human hypothalamic
hamartoma slices immediately after surgical resection (Wu
et al. 2005). Similarly, glutamate and NMDARs agonists in
the presence of glycine increased membrane-depolarization
currents in neuroblastoma cells (North et al. 1997), and
glioblastoma, astrocytoma, and oligodendroglioma cells
responded to kainate by depolarization of tumor cells in
culture or tissue slices (Labrakakis et al. 1998).
It was also demonstrated that iGluRs are active and
functional in cancer cells derived from peripheral tumors.
An analysis of whole-cell patch-clamp recordings of
membrane currents proved that in A549 lung cancer and
TE671 (rhabdomyosarcoma/medulloblastoma) cell lines
application of glutamate (10 mM) resulted in inward cur-
rents that were almost completely blocked by application
of NMDA and AMPA receptor antagonists. Interestingly,
the evoked currents were small, which is consistent with
the low expression of these receptors in examined cancer
cells (Stepulak et al. 2009).
Importantly, experimental data have also implicated
important role of mGluRs in malignant tumor metabolism
and progression. Likewise iGluRs, metabotropic receptors
were first detected in tumors of CNS origin such as gliomas
(Albasanz et al. 1997; Condorelli et al. 1997), ganglio-
gliomas and dysembryoplastic neuroepithelial tumors
(Aronica et al. 2001). Interestingly, mGluR3 receptors
were present in almost all of the glioma tumor samples
(Nicoletti et al. 2007), including glioma initiating cells
(Ciceroni et al. 2008) and glioma cell lines (Nicoletti et al.
2007) with exception of the U343 cell line (Stepulak et al.
2009). In contrast, mGluR1 and mGluR5 were highly
represented in the neuronal components of brain tumors
(Aronica et al. 2001). In pediatric CNS tumors, the
metabotropic glutamate receptor subtypes mGluR1,
mGluR2, mGluR4, mGluR5 and mGluR6 were expressed
at higher levels in the malignant tumors than in low-grade
astrocytomas. Glioblastoma, ependymoma and low-grade
astrocytoma all showed low expression levels of mGluR8,
whereas expression of mGluR8 was firmly up-regulated in
medullo-blastomas (Brocke et al. 2010). Similarly, most of
the analyzed medulloblastoma tissue samples and medul-
loblastoma cell lines displayed the presence of mGluR4
receptors, which inversely correlated with tumor growth
(Iacovelli et al. 2006).
Parallel to CNS tumors, mGluRs have been shown to be
over-expressed in some types of peripheral cancers and
neoplasms. High expression of mGluR1 was reported in
primary and metastatic prostate cancers, in contrast to non-
cancerous prostate tissues in immunohistochemical ana-
lysis (Koochekpour et al. 2012). Moreover, mGluR1
expression displayed a cell type-dependent pattern, being
higher in androgen-independent and metastatic cell lines
rather than in androgen-sensitive or primary prostate can-
cer cell lines (Koochekpour et al. 2012). mGluR1/2/3/4/5
expression was demonstrated in both androgen-dependent
PC-3 and androgen-independent LNCaP prostate cancer
cell lines, whereas mGluR6/8 were present in LNCaP cells
only (Pissimissis et al. 2009). mGluR4 was reported to be
more specifically expressed in colorectal cancers than in
normal tissues (Chang et al. 2005); different mGluR
combinations were also demonstrated in colon cancer
derived cell lines, including LS180 cell line, where all
mGluRs types were detected (Stepulak et al. 2009). Given
the fact that mGluR4 mediates 5-fluorouracil resistance in
human colon cancer cells, which is a major obstacle in
chemotherapy of this cancer type (Yoo et al. 2004), it
seems that the presence of mGluR4 in some cancers could
have functional significance. mGluR4 was also present in
the 50 % of immunohistologically analyzed laryngeal
carcinomas, with lower expression in stomach, gall bladder
and pancreas adenocarcinomas (17–33 %). Very low pre-
sence of mGluR4 was demonstrated in thyroid, adrenal
glands, and kidney cancers (8–13 %), whereas it was not
detected in esophageal, endometrial and prostate cancers,
as well as in neoplasms derived from salivary glands and
testis (Chang et al. 2005). Single studies presented an
expression of different mGluRs in several cancer cell lines,
including those originating from thyroid and breast cancers
and blood malignancies (Stepulak et al. 2009), laryngeal
carcinomas (Stepulak et al. 2011), and osteosarcomas
(Kalariti et al. 2004).
Recent studies proved that mGluR1 are responsible for
cell growth regulation in breast (Speyer et al. 2012) and
renal cancer cells (Martino et al. 2013), both in vitro and
in vivo; simultaneously their presence was not found in
oral cancer tissues and cell lines, in contrast to mGluR5,
which was present in the majority of oral cancer specimens
and weakly in adjacent dysplastic oral mucosa (Park et al.
2007). Moreover, melanoma development was connected
with the presence of mGluR1 receptors (Ohtani et al.
2008), a finding that was supported by observations
showing its expression in melanoma cell lines and mela-
noma samples, but not in normal melanocytes and benign
nevi (Pollock et al. 2003).
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Taken all together, considerable evidence exists for
glutamate receptors expression in a variety of tumors and
cancer cell lines along with proofs that they are functional,
thereby might play an important role in neoplastic trans-
formation and cancer progression.
The role of GluRs in cancer
To substantiate the hypothesis that glutamate receptors are
functionally important for tumor growth, several studies
evaluated their involvement in tumorigenesis and subse-
quently proved that at least some of the GluRs might have
oncogenic properties. The impact of metabotropic gluta-
mate receptors on tumor growth was highlighted by a series
of experiments which showed causal relationship between
mGluR1 expression and melanoma development. Chen’s
group was the first to demonstrate that ectopic expression
of mGluR1 in melanocytes, which normally lack this
receptor, was sufficient to induce transformation to
malignant melanoma in vivo (Pollock et al. 2003). In
subsequent studies, which implemented an inducible siR-
NA system, they were able to show that mGluR1 was
indispensable for the maintenance of transformation of
immortalized melanocytes into tumors with short 3–5 days
latency. Their tumorigenic potential in both immunodefi-
cient nude and syngenic mice suggested that the immune
system does not influence either tumors formation or dis-
tant intestine and muscle metastases formation (Shin et al.
2008). Direct evidences for mGluR1-driven melanoma
formation and progression were provided in the same year
by Ohtani and coworkers who showed that mGluR1 con-
ditionally expressed in melanocyte-induced pigmented
lesions at the first stage, followed by appearance of mela-
noma tumors 52 weeks after transgene activation. When
the transgene was inactivated, melanoma growth was
inhibited as compared to animals bearing tumors with
persistent mGluR1 expression (Ohtani et al. 2008). Similar
findings were reported for mGluR5 transgene activation in
mice, resulting in skin hyperpigmentation, seconded by
melanoma tumor formation with metastases or primary
melanoma lesions detected in lymph nodes, lungs, spleen,
liver, uvea and meninges that eventually penetrated into the
skull bones (Choi et al. 2011). Very recently, oncogenic
mGluR1 properties were also attributed to epithelial cells.
Mouse kidney epithelial cells displayed in vivo tumorige-
nicity, when transfected to ectopically express functional
mGluR1, resulting in tumor formation in nude mice. Par-
allel, siRNA-mediated inhibition of mGluR1 expression in
renal cancer cells impaired tumor growth in vivo, thus
suggesting that sustained expression of mGluR1 is neces-
sary for neoplastic transformation and tumor progression
(Martino et al. 2013), whereas targeting mGluR1 gene
using shRNA-expressing lentiviral construct reduced
growth of breast cancer cells both in vitro and in vivo
(Speyer et al. 2012).
Changes in the levels of expression of ionotropic glu-
tamate receptors or their single subunits in experimental
conditions were also demonstrated to be important for
cancer cells proliferation and invasion, which suggests the
involvement of GluRs in cancer progression. As demon-
strated in knockout experiments, diminished expression of
GluR1 (AMPAR) subunit at mRNA and protein levels
inhibited proliferation of glioma cells in vitro and in vivo
(de Groot et al. 2008). Another study presented that RNAi-
mediated suppression of GluR1 or GluR2 did not affect
pancreatic cancer cell growth, however significantly
decreased invasion in vitro, and inhibited tumor cell set-
tling in a mouse model in vivo (Herner et al. 2011). Sim-
ilar, knock-down of the GluR3 gene reduced proliferation
and migration, as well as enhanced apoptosis of pancreatic
cancer cells, while over-expression of this gene was
reported to have opposite effect in vitro and in a subcuta-
neous xenograft model (Ripka et al. 2010). In contrast, the
silencing of GluR2 by siRNA transfection increased glioma
cell proliferation (Beretta et al. 2009), whereas gene
silencing of GluR4 modulated the mRNA expression of
various tumor-suppressor genes, oncogenes and other
genes involved in invasion, adhesion and metastatic capa-
bilities, which resulted in significant increase of cell via-
bility of human rhabdomyosarcoma/medulloblastoma
(TE671) and human multiple myeloma RPMI8226 cells.
Additionally, silencing of GluR4 stimulated migration of
TE671 cells (Luksch et al. 2011). Similarly to AMPAR
subunits, modulation of expression of genes for NMDAR
subunits influenced behavior of cancer cells. Silencing the
NR2A subunit-targeted gene inhibited gastric cancer cells
proliferation and cell cycle progression resulting in
increased proportion of cells in G1 phase (Watanabe et al.
2008). TE671 and A549 lung cancer cells demonstrated
reduced cell viability after transfection and specific
knockdown of NR1 gene (Luksch et al. 2011).
Importantly, the expression of GluRs as well as their
function in cancer development and progression is influ-
enced by genomic and epigenetic modifications resulting in
aberrant posttranscriptional processing. Causative for the
aberrant cellular function of glutamate receptors in cancer
are changes in genomic sequences for mGluRs and selected
subunits of iGluRs. Of particular importance is the notion
that the presence of rearranged or mutated forms of glu-
tamate receptor subunits might activate cancer cell growth.
As mentioned above, insertional mutagenesis of an ectop-
ically expressed mGluR1 in mouse results in melanoma
development (Pollock et al. 2003). Likewise, somatic
mutations within mGluR3 gene result in an activation of
GPCR-mediated mitogen-activated protein kinase 1/2
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signaling that results in a transformed cells’ phenotype,
which renders an increased migration of melanoma cells
along with a loss of anchorage dependency in growth
regulation (Prickett et al. 2011). Moreover, a very recent
study highlighted the importance of naturally occurring
GRM1 somatic mutations for mGluR1 surface expression,
altered basal and agonist-dependent activity, and disruption
of intracellular signaling pathways downstream of the
receptor, including inositol phosphate (IP) formation, and
altered ERK1/2 kinases activity (Esseltine et al. 2013).
Since these mutations were identified in different types of
neoplasms including lung adeno- and SCC (Kan et al.
2010), colorectal cancers (Sjoblom et al. 2006), and glio-
blastoma (Parsons et al. 2008), it has been hypothesized
that they are relevant and contribute to a cancer phenotype
(Esseltine et al. 2013). Clinical genetic analysis of GRM1
showed that single nucleotide polymorphism of the C allele
of rs362962 (coding mGluR1) contributes to human mel-
anoma susceptibility, especially in a subgroup of patients
with a low level of sun exposure and tumors located on the
trunk and extremities (Ortiz et al. 2007). A similar study
performed in women carrying breast cancer revealed a
significant correlation between the GRM1 CC genotype of
rs362962 and the development of hormone receptor-nega-
tive breast cancer and association of rs6923492 and
rs362962 genotypes with age at diagnosis (Mehta et al.
2013).
In contrast to metabotropic receptors, somatic mutations
of iGluR subunits in cancers were scarcely investigated.
Whole-exome sequencing analysis revealed moderate to
high prevalence of somatic mutations in genes coding
NR2A, and NR1 subunits of NMDA receptors in mela-
noma (Wei et al. 2011); however, their possible conse-
quences are not known (Prickett and Samuels 2012).
Nonetheless, in addition to genetic rearrangements,
epigenetic alterations seem to play an important role in
cancer development and progression. Human cancers are
characterized by a global impairment of DNA methylation.
Still, hypermethylation of some DNA regions, especially at
the promoter CpG islands of tumor-suppressor genes, is
observed (Virani et al. 2012). In this context, considerable
interests were demonstrated regarding methylation status
of NMDAR subunits: NR2A and NR2B promoters. Aber-
rant promoter CpG islands hypermethylation of GRIN2B
(NR2B coding gene) during breast cancer progression was
reported, showing higher methylation levels and frequen-
cies in ductal carcinoma in situ when compared with pre-
invasive lesions such as flat epithelial atypia or atypical
ductal hyperplasia; significantly higher methylation fre-
quencies in grade III than in grade I of invasive ductal
carcinoma have also been shown which suggests that CpG
island methylation of GRIN2B might be an early event in
breast cancer progression (Park et al. 2011). Other groups,
on the other hand, found that NR2B promoter methylation
exhibits tumor-suppressive activity in human esophageal
(Kim et al. 2006) and gastric cancers (Liu et al. 2007), as
well as in non-small cell lung carcinoma (Tamura et al.
2011). Aberrant methylation status of NR2B promoter was
present in more than 60 % of human gastric and non-small
cell lung carcinoma samples, whereas the GRIN2B meth-
ylation status alterations were found in no more than 5 %
of corresponding normal tissues (Liu et al. 2007; Tamura
et al. 2011). Interestingly, gene methylation of NR2B
displayed an inverse correlation with gene (Kim et al.
2006) or protein (Tamura et al. 2011) expression, sug-
gesting that NR2B inactivation occurs mainly through
epigenetic events (Kim et al. 2006). Moreover, reintro-
duction of this gene in esophageal cancer or forced
expression in gastric cancer cell lines was accompanied by
apoptosis or inhibited cell colony formation, respectively,
suggesting tumor-suppressor activity for NR2B (Kim et al.
2006; Liu et al. 2007). Recently, the same research group
demonstrated similar results for NR2A subunit in colo-
rectal cancers (Kim et al. 2008). In a more clinically ori-
ented analysis, NR2B methylation was significantly
associated with a better prognosis regarding survival of
patients with SCC rather than those with adenocarcinoma
(Tamura et al. 2011). Therefore, rearrangements of gluta-
mate receptors at different genetic and epigenetic levels
seem to play a distinct role in their expression and function.
Despite the fact that the issue at hand requires more
extensive studies, one may already hypothesize that dif-
ferent modifications of GluRs and their respective genes
exist in cancer cells, as demonstrated recently by the dis-
covery of new spliced variants of human GRM1 gene in
melanoma cells (DiRaddo et al. 2013).
Potential clinical significance of GluRs in cancer
The unequivocally proven role of GluRs in oncogenesis
turned attention towards their potential clinical significance
in different types of tumors. Thus, in the clinical settings
the expression of glutamate receptors might influence his-
tological differentiation, clinical tumor staging, the pre-
sence of metastases and/or overall patient survival rate.
One of the key features that distinguish various tumors
relates to their histological differentiation and histological
signs of malignancy, classified as tumor grading that
influences tumor’s malignancy potential and its clinical
course. It has been reported that glutamate receptors’
expression is associated with differentiation status in a
variety of tumor subtypes. In pancreatic cancer, precursor
lesions as well as pancreatic intraepithelial neoplasia
AMPAR GluR1 subunit levels were increased in a step-
wise manner, suggesting glutamate involvement in a
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malignant transformation. On the other hand, however, the
expression of GluR1, GluR2 and GluR4 subunits was
down-regulated in PDAC (Herner et al. 2011). Moreover,
in other tumor types a direct relationship between the
degree of malignancy and GluRs expression was found. In
brain tumors, GluR1 subunit was differentially expressed
according to the tumor grading, being elevated in glio-
blastomas when compared with anaplastic astrocytomas
and low-grade astrocytomas, hence correlating with tumor
aggressiveness (de Groot et al. 2008). Opposite association
was observed when expression of GluR2 was analyzed,
which proved to be present in slow-growing GBM-derived
tumor stem cells (GBM TSCs) and low-grade tumor sam-
ples but not in fast-growing gliomas or high-grade tumor
specimens, indicating that GluR2 expression is associated
with a low degree of malignancy (Beretta et al. 2009).
Likewise, immunohistochemistry with an anti-GluR2
antibody showed a significant difference in the positivity of
staining that was uniformly present in virtually 100 % of
benign secretory prostatic epithelium when compared with a
high-grade prostatic intraepithelial neoplasia and low Glea-
son-patterned carcinomas where scarcely any or very low
immunoreactivity of GluR2 was observed. This suggests that
the presence of GluR2 in benign glands, including post-
atrophic and adenosis-type ones, readily distinguishes them
from prostate cancer (Hechtman et al. 2012). An opposite
pattern was observed in normal oral mucosa showing very
weak expression of NR1 subunit of NMDAR, whereas
majority of analyzed oral SCC specimens expressed this
subunit; albeit the presence of NR1 did not correlate with
histological grading of this cancer type (Choi et al. 2004).
Another study that implemented human tissue microarrays
revealed that NMDAR subunit NR2B expression was asso-
ciated with the HER2-positive breast cancer subtype, in
contrast to the luminal subtype, where NR2B expression was
not observed (Li and Hanahan 2013). In medulloblastoma,
mGlu4 receptor immunoreactivity highly correlated with the
histological features showing decreasing expression levels of
this receptor in the following rank order: nodular desmo-
plastic[ classic  large-cell anaplastic tumors (Iacovelli
et al. 2006).
Notably, cancer progression results in tumor growth and
local or distant metastases development. The relationship
between GluRs expression and aforementioned clinical
features of cancers has been scarcely investigated though.
Only a few reports demonstrated that the tumor size, pre-
sence of lymph node metastases and cancer stage were
significantly related to high NR1 (Choi et al. 2004) and
mGluR5 (Park et al. 2007) expression in oral SCC, whereas
significantly lower expression levels of mGlu4 receptors
were correlated with spinal cord metastases, CSF spread-
ing, and recurrence of medulloblastoma (Iacovelli et al.
2006).
Tumor progression along with its dissemination and
recurrence are closely related to patients’ prognosis and
overall survival. It has been demonstrated that NR1 subunit
expression was associated with unfavorable outcome in
patients with oral SCC (Choi et al. 2004), whereas mGluR5
expression showed positive correlation with an overall
survival of patients with the same malignancy (Park et al.
2007). Similarly, in medulloblastoma the expression of
mGluR4 was higher in patients, who survived 5-year after
surgery (Iacovelli et al. 2006). On the contrary, overex-
pression of mGluR4 is associated with a poor prognosis in
colorectal carcinoma (Chang et al. 2005). Interestingly,
GluR2 expression showed a significant correlation with
longer progression-free and overall survivals and was
down-regulated in chemoresistant tumors, proving to be a
positive prognostic factor for patients with advanced serous
papillary ovarian adenocarcinoma (Choi et al. 2012). Gene
expression analysis of several hundred glioblastoma sam-
ples revealed that a loss of GRIA2 (gene for GluR2)
expression was 1 of the 38 gene changes that predict a poor
prognosis in glioblastoma (Colman et al. 2010).
Whenever high NR2B expression levels correlated with
high vGluT2 vesicular glutamate transporter expression,
the survival of patients bearing glioblastoma was signifi-
cantly shorter, when compared with the patients groups that
expressed low levels of NR2B/vGLUT2 (Li and Hanahan
2013).
Concluding remarks
Research into the role of Glu signaling in cancer devel-
opment and progression is still in its infancy; however,
important progress has been made in recent years. Con-
siderable evidence exists and indicates that glutamate plays
an important role in tumor development, acting as a growth
factor and a signal mediator in neural as well as non-neu-
ronal tumors tissues, in both autocrine and paracrine
fashions. It has been proven that its actions involve mainly
a family of receptors consisting of metabotropic glutamate
receptors and ionotropic glutamate receptors whose pre-
sence has been proven in a variety of benign and malignant
lesions throughout the body. Their actions, however, might
differ significantly due to the fact that GluRs are combined
from various subunits, which result in a large diversity of
intracellular signaling and distinct pharmacological prop-
erties. Moreover, receptor subunits such as the NR1 subunit
of the NMDA receptor are prone to post-transcriptional
events (RNA editing and alternative splicing of RNA),
which may result in distinct isoforms (for example eight in
case of NR1 subunit) due to the presence of independent
sites of alternative splicing. On top of that receptor sub-
units might undergo further posttranslational and
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epigenetic modifications resulting in even more complex
glutamate signal transduction. Thus, the clinical signifi-
cance of glutamate receptor expression may differ among
tumor entities and it is difficult to predict how the
expression of a particular subunit will influence cancer
behavior. Still, it is tempting to speculate that GluRs and
their signaling pathways render promising targets for
therapeutic interventions. As a matter of fact, in recent
years, there have been multiple attempts to implement
iGluR and mGluR antagonists, in particular in malignant
glioma treatment. Drugs such as AMPAR/KR inhibitors,
ZK 200775 and GYKI 52466, despite having little effect on
glioma growth in vitro, have been shown to exert anti-
proliferative and anti-excitotoxic effects in rat hippocampal
glioma models. Similar results were obtained for the
NMDAR antagonists, norketamine 72 and MK801 (me-
mantine). In fact, memantine has even been employed in a
Phase II clinical trial to determine its safety/efficacy in
glioma patients; however, results are not yet available
(http://Clinicaltrials.gov #NCT01260467). Similarly, the
effectiveness of talampanel (an AMPAR antagonist)
against glioma has been explored in the clinic. This study
was completed with results that were not encouraging
though (de Groot and Sontheimer 2011). Interestingly,
despite all of the preclinical work and clinical trials (in
progress or completed) involving iGluR antagonists, stud-
ies targeting mGluR in glioma treatment are lacking.
mGluRs, being able to form functional homodimers as
typical GPCRs, are considered more susceptible to anti-
cancer drug design (Willard and Koochekpour 2013) and
may constitute better drug targets than iGluRs (Teh and
Chen 2012). Yet, no clinical trials are currently ongoing.
Future studies in this field are clearly needed to determine
the efficacy of mGluR antagonists and Glu release inhibi-
tors such as riluzole against tumors.
It is clear that more research is needed to define the
clinical significance of Glu–GluR expression and signaling
in various cancers. Given existing preliminary studies, it
will be extremely interesting to follow the field of gluta-
matergic signaling in cancer in future years.
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